Pfizer's Upjohn has merged with Mylan to form Viatris
Closed portfolio with a later-stage archive tilt
According to ClinicalTrials.gov-derived indexes, Pfizer's Upjohn has merged with Mylan to form Viatris sits in the top decile of US sponsors by registered trial count (#186 of 15,742 sponsors by registered trial count).
Pfizer's Upjohn has merged with Mylan to form Viatris: 158 sponsored US clinical trials, none currently recruiting.
Pfizer's Upjohn has merged with Mylan to form Viatris sponsors 158 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 138 completed. 128 of these trials are in Phase 3-4 (later-stage) and 24 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Healthy, with 3 trials.
Top-decile sponsor footprint
Pfizer's Upjohn has merged with Mylan to form Viatris ranks in the top decile of sponsors by registered trial count (#186 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
138 of 158 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (87.3%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
158 total, page 4 of 4
Study to Assess the Longterm Safety of Sildenafil Citrate in Patients With Pulmonary Arterial Hypertension
NCT00159887
To Evaluate the Safety and Effectiveness of Atorvastatin Plus a Cholinesterase Inhibitor in AD Patients.
NCT00151502
A Study to Investigate the Effects on Blood Pressure and Pulse Rate of a Single 100mg Dose of Sildenafil in Patients With Benign Prostatic Hyperplasia Who Are Being Treated With Doxazosin
NCT00645034
A Ten-Week Study Evaluating The Effectiveness And Safety Of Zoloft In Children And Adolescents With A Diagnosis Of PTSD
NCT00150306
A Study to Assess the Efficacy and Safety of 20, 40, and 80mg of Sildenafil Three Times a Day in the Treatment of Pulmonary Arterial Hypertension
NCT00644605
Efficacy and Safety of Celecoxib Versus Ibuprofen in the Treatment of Osteoarthritis of the Knee (United States)
NCT00620867
Comparison of Latanoprost With Travoprost and Bimatoprost in Patients With Elevated IOP. A 12-weeks, Masked Evaluator, Phase IV Multi-center Study in the US
NCT00847483
A Study of Glaucoma or Ocular Hypertension in Patients Within the United States
NCT00800267
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 19 |
| Phase 2 | 5 |
| Phase 3 | 75 |
| Phase 4 | 53 |
How the Pfizer's Upjohn has merged with Mylan to form Viatris archive is shaped
158 indexed studies, none listed as recruiting (0% open); 138 completed (87%).
Phase mix: 128 late (III/IV) vs 24 early (I/II) (later-stage heavy).
Top condition: Healthy (3 trials), 9 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Pfizer's Upjohn has merged with Mylan to form Viatris: archived-pipeline peers nationwide
Peers matched on 158 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Pfizer's Upjohn has merged with Mylan to form Viatris sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 158 archived trials
- Galderma R&D · 158 trials · 4% recruiting
- Ann & Robert H Lurie Children's Hospital of Chicago · 159 trials · 19% recruiting
- University of South Carolina · 157 trials · 19% recruiting
- Alexion Pharmaceuticals · 162 trials · 10% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Pfizer's Upjohn has merged with Mylan to form Viatris page
158 registered trials is a research-attention snapshot, not an endorsement of Pfizer's Upjohn has merged with Mylan to form Viatris or any single study.
- None of Pfizer's Upjohn has merged with Mylan to form Viatris's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Healthy is the condition Pfizer's Upjohn has merged with Mylan to form Viatris studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Healthy trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Pfizer's Upjohn has merged with Mylan to form Viatris pipeline card: 158 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.